Arginine Butyrate
Lympho-proliferative Diseases
HemaQuest Pharmaceuticals Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
28 Active assets in the Lympho-proliferative Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darbepoetin Alfa Mayo Clinic | Phase 3 | BB |
Epoetin Alfa Mayo Clinic | Phase 3 | BB |
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 2 | BB |
Tabelecleucel Pierre Fabre Medicament | Phase 3 | BB |
American Ginseng Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Arginine Butyrate is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →